Hanmi FC to invest 10 billion KRW for building facilities for ‘high-tech CDMOs’

South Korea-based Hanmi Fine Chemical, a subsidiary of Hanmi Pharmaceutical Group specialising in APIs (Active Pharmaceutical Ingredients) development & manufacturing, is now accelerating a new business, expanding its specialties from ongoing APIs to ‘hightech CDMO’ services. To this end, Hanmi FC will invest about 10 billion KRW to build facilities for ‘high-tech CDMOs’. Last year, Hanmi FC was selected to conduct the Korean government’s project for expanding production facilities for COVID-19 vaccines & raw materials and received 1.6 billion KRW in support of such efforts. Furthermore, the company plans to upgrade these facilities even more by supplementing 8 billion KRW from its own funds. Hanmi FC is currently in charge of the development & production of raw materials for Hanmi Pharmaceutical’s innovative new drugs, including Belvarafenib (in partnership with Genentech), MKI (in partnership with Aptose), & Poziotinib (in partnership with Spectrum).